Oppenheimer Asset Management Inc. Fibrogen Inc Transaction History

Oppenheimer Asset Management Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 03, 2021	SELL	$18.57 - $35.68 $175,207 - $336,640	-9,435 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $7,533 - $13,539	-243 Reduced 2.51%	9,435 $327,000
Q4 2020 Feb 11, 2021	SELL	$37.09 - $48.97 $264,859 - $349,694	-7,141 Reduced 42.46%	9,678 $359,000
Q3 2020 Nov 13, 2020	BUY	$40.47 - $45.5 $210,970 - $237,191	5,213 Added 44.92%	16,819 $692,000
Q2 2020 Aug 11, 2020	BUY	$32.57 - $42.83 $3,094 - $4,068	95 Added 0.83%	11,606 $470,000
Q1 2020 May 08, 2020	SELL	$23.3 - $45.96 $4,776 - $9,421	-205 Reduced 1.75%	11,511 $400,000
Q4 2019 Feb 07, 2020	BUY	$34.58 - $48.06 $42,118 - $58,537	1,218 Added 11.6%	11,716 $502,000
Q3 2019 Oct 31, 2019	SELL	$36.98 - $48.45 $7,359 - $9,641	-199 Reduced 1.86%	10,498 $388,000
Q2 2019 Aug 09, 2019	BUY	$35.13 - $55.53 $33,197 - $52,475	945 Added 9.69%	10,697 $483,000
Q1 2019 Apr 24, 2019	BUY	$42.83 - $59.91 $417,678 - $584,242	9,752 New	9,752 $530,000
Q3 2018 Oct 26, 2018	SELL	$56.3 - $67.25 $212,082 - $253,330	-3,767 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$44.9 - $64.95 $169,138 - $244,666	3,767 New	3,767 $236,000
Q1 2018 May 09, 2018	SELL	$45.35 - $61.65 $199,993 - $271,876	-4,410 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $147,294 - $237,699	4,410	4,410 $237,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.